Rational HIV immunogen design to target specific germline B cell receptors

Science

Volumn 340, Issue 6133, 2013, Pages 711-716

  Jardine, Joseph ^a,b   Julien, Jean Philippe ^a   Menis, Sergey ^a,b   Ota, Takayuki ^a   Kalyuzhniy, Oleksandr ^a,b   McGuire, Andrew ^c   Sok, Devin ^a   Huang, Po Ssu ^b   MacPherson, Skye ^a,b   Jones, Meaghan ^a,b   Nieusma, Travis ^a   Mathison, John ^a   Baker, David ^b   Ward, Andrew B ^a   Burton, Dennis R ^a,d   Stamatatos, Leonidas ^c,e   Nemazee, David ^a   Wilson, Ian A ^a   Schief, William R ^a,b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; B LYMPHOCYTE RECEPTOR; CD4 ANTIGEN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NANOPARTICLE; NEUTRALIZING ANTIBODY; OD GT6 ANTIGEN; UNCLASSIFIED DRUG; VRC01 ANTIBODY;

ANTIBODY; DISEASE TREATMENT; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; PATHOGEN; PROTEIN; VACCINE;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE ACTIVATION; BINDING AFFINITY; CRYSTALLOGRAPHY; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; GERM LINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84877609579     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1234150     Document Type: Article

References (30)

1. S. A. Plotkin, Clin. Vaccine Immunol. 17, 1055 (2010).
2. D. R. Burton, P. Poignard, R. L. Stanfield, I. A. Wilson, Science 337, 183 (2012).
3. W. R. Schief, Y.-E. A. Ban, L. Stamatatos, Curr. Opin. HIV AIDS 4, 431 (2009).
4. D. R. Burton et al., Cell Host Microbe 12, 396 (2012).
5. D. C. Ekiert et al., Science 324, 246 (2009).
6. P. Zhang et al., Proc. Natl. Acad. Sci. U.S.A. 106, 7537 (2009).
7. J. P. Julien, P. S. Lee, I. A. Wilson, Immunol. Rev. 250, 180 (2012).
8. L. Kong et al., Proc. Natl. Acad. Sci. U.S.A. 109, 9499 (2012).
9. D. R. Burton, Nat. Rev. Immunol. 2, 706 (2002).
10. X. L. Wu et al., Science 329, 856 (2010).
11. J. F. Scheid et al., Science 333, 1633 (2011).
12. X. Wu et al.; NISC Comparative Sequencing Program, Science 333, 1593 (2011).
13. T. Q. Zhou et al., Science 329, 811 (2010).
14. R. Diskin et al., Science 334, 1289 (2011).
15. A. P. West Jr., R. Diskin, M. C. Nussenzweig, P. J. Bjorkman, Proc. Natl. Acad. Sci. U.S.A. 109, E2083 (2012).
16. R. Arnaout et al., PLoS ONE 6, e22365 (2011).
17. R. Pejchal et al., Science 334, 1097 (2011).
18. A. Leaver-Fay et al., Methods Enzymol. 487, 545 (2011).
19. G. Chao et al., Nat. Protoc. 1, 755 (2006).
20. G. R. Abecasis et al.; 1000 Genomes Project Consortium, Nature 491, 56 (2012).
21. M. F. Bachmann, G. T. Jennings, Nat. Rev. Immunol. 10, 787 (2010).
22. X. Zhang, W. Meining, M. Fischer, A. Bacher, R. Ladenstein, J. Mol. Biol. 306, 1099 (2001).
23. T. Ota et al., J. Immunol. 189, 4816 (2012).
24. S. Hoot et al., PLoS Pathog. 9, e1003106 (2013).
25. C. Sundling et al., J. Exp. Med. 207, 2003 (2010).
26. K. L. Knight, C. R. Winstead, Curr. Opin. Immunol. 9, 228 (1997).
27. H71 would not be accessible for binding because it forms internal H bonds with backbone carbonyl groups (fig. S19).
28. B. F. Haynes, G. Kelsoe, S. C. Harrison, T. B. Kepler, Nat. Biotechnol. 30, 423 (2012).
29. E. Krissinel, K. Henrick, J. Mol. Biol. 372, 774 (2007).
30. E. F. Pettersen et al., J. Comput. Chem. 25, 1605 (2004).